Driehaus Capital Management’s PTC Therapeutics PTCT Stock Holding History

Driehaus Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$69.2M	Sell	1,015,772 -120,416	-11%	-$8.53M	0.51%	54
2025 Q4	$86.3M	Buy	1,136,188 +4,439	+0.4%	+$323K	0.59%	45
2025 Q3	$69.5M	Buy	1,131,749 +72,723	+7%	+$3.79M	0.5%	63
2025 Q2	$51.7M	Sell	1,059,026 -453,619	-30%	-$21.5M	0.41%	75
2025 Q1	$77.1M	Buy	1,512,645 +471,586	+45%	+$23.5M	0.74%	33
2024 Q4	$47M	Buy	+1,041,059	New	+$44.6M	0.39%	92
2015 Q2	–	Sell	-12,329	Closed	-$750K	–	567
2015 Q1	$750K	Buy	+12,329	New	+$752K	0.03%	430

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Driehaus Capital Management's PTCT Position: Q1 2026 in Review

Driehaus Capital Management reduced its PTC Therapeutics (PTCT) stake by 11% in Q1 2026, selling an estimated $8.53M and leaving 1,015,772 shares worth $69.2M. The position accounts for 0.51% of the portfolio, ranked #54.

Driehaus Capital Management first reported a position in PTCT in Q1 2015 and has held it in 7 quarters since. The position peaked at $86.3M in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

Driehaus Capital Management held 1,015,772 shares of PTC Therapeutics worth $69.2M as of Q1 2026.
Driehaus Capital Management sold 120,416 PTC Therapeutics shares in Q1 2026, an estimated $8.53M.
PTC Therapeutics made up 0.51% of Driehaus Capital Management's portfolio in Q1 2026, its #54 holding.
Driehaus Capital Management first reported a position in PTC Therapeutics in Q1 2015 and has held it in 7 quarters since.
Driehaus Capital Management's PTC Therapeutics position peaked at $86.3M in Q4 2025.
349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.